The goal of “BDA workshop Improving oncology drug development for children and adolescents” is to state where we are, to identify how the strategy for pediatric oncology drug development should be further defined and to propose solutions that may improve the implementation of the regulation in order to better meet the needs of children and adolescents with cancer.
This is a meeting where all stakeholders, namely academia, parents and patients, industry, regulators, policymakers and others will share their views and challenges, will interact and propose solutions and actions for the future. This meeting is not aimed to be a consensus meeting.
The meeting will first address where we are at year 5 of the European pediatric regulation in the field of oncology and will follow on the actions proposed during the first BDA meeting in December 2011.
Discussions will be focused on three topics of major importance for the future:
- Mechanism-of-action and biology driven development of oncology drugs for children and adolescents
- New and innovative partnering for improving cooperation between stakeholders
- Novel designs and development plans to improve feasibility and speed up introduction of new drugs in standard care.
Who should attend?
- Representatives from Academia (scientists, clinicians)
- Representatives from the Pharmaceutical Industry (senior decision makers from pediatric oncology, drug developers, regulators, public affairs).
- Representatives of European regulatory bodies
- Parents and Patient Advocates
Contact: Marjorie Recorbet, +32 2 775 02 15, [email protected]